New procedure aims to save vision of children with eye cancer

April 14, 2010
Retinoblastoma patient Savannah Smith and her mother, Courtney, before a recent appointment with J. William Harbour, M.D., at the Center for Advanced Medicine. Savannah had a radioactive plaque implanted Feb. 26 at St. Louis Children's Hospital. Credit: Robert Boston Washington University School of Medicine

An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes.

J. William Harbour, MD, is one of only a few doctors nationwide to use the approach for treating a rare, childhood eye cancer, called retinoblastoma. Harbour, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences, performs the surgery at St. Louis Children's Hospital. He implants a small disc, or plaque, which stays in the eye for three days before a second surgery to remove it.

"The standard of care for retinoblastoma is chemotherapy, followed by laser and freezing treatments to eliminate the last remnants of tumors," Harbour says. "But occasionally there will be a tumor that doesn't respond to chemotherapy or is too large to treat with a laser or freezing treatment. That's where this plaque treatment comes in. It gives us an option that may allow us to save the eyes of a young child."

Retinoblastoma, as the name suggests, is characterized by tumors in the eye's . It is extremely rare, affecting about one child in 20,000. In the United States, about 200 children each year are diagnosed with retinoblastoma. Approximately 40 percent of them develop tumors in both eyes, so in cases where the tumors prove resistant to chemotherapy, very young children and their parents are faced with a choice between a life without eyes and a high risk of death.

The video will load shortly.
An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes. One of only a few doctors in the nation using this approach, J. William Harbour, MD, is treating a rare childhood cancer, called retinoblastoma, which is characterized by tumors in the eye's retina. In the United States, about 200 children each year are diagnosed with the disorder. Harbour, the director of ocular oncology at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, has recently started using the method to treat the cancer and possibly save the eyes. Credit: Washington University in St. Louis

That's why Harbour, also a professor of cell biology and of molecular oncology and director of ocular oncology at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and a handful of other eye cancer specialists have recently started using the plaque method to treat the cancer and possibly save the eyes.

"The treatment plaque looks like a bottle cap made of gold," Harbour says. "Radiation seeds are placed on one side of the plaque, shining the radiation in one direction like a flashlight focused on the tumor. That prevents the radiation from affecting other parts of the body."

The plaques contain seeds that deliver radiation directly to the tumor cells. Harbour says because the radiation gets to the tumor in a much more focused way than was possible in the past, it is not likely that these plaques will contribute to future problems in or around the eye.

Implantation of radioactive plaques has been relatively common in adult patients with a different eye cancer called ocular melanoma. The gold discs have been the standard of care for those patients for decades, and results to date in an ongoing National Institutes of Health (NIH) study have demonstrated that the plaques are an effective treatment in adults with ocular melanoma.

Although the NIH study showed that plaque therapy is as effective as eye removal in preventing the spread of ocular melanoma, the small number of children who have retinoblastoma make it unlikely a similar study could be conducted for that form of . He estimates only about 10 to 20 children per year will require the plaque therapy in the United States.

The video will load shortly.
An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs into the eyes of children with a rare cancer in an attempt to save their vision and their eyes. The surgery involves a small disc, or plaque, which stays in the eye for three days before a second operation to remove it. Most kids with the form of cancer called retinoblastoma get chemotherapy, followed by laser and freezing treatments to eliminate the last remnants of tumors. But occasionally tumors don’t respond. Retinoblastoma is extremely rare. In the United States, about 200 children each year are diagnosed with the cancer, and approximately 40 percent develop tumors in both eyes. It’s important to have another option for those kids who don’t do well with chemotherapy because the only other treatment option is complete removal of the eye. Credit: Washington University BioMed Radio

Harbour says it takes several weeks to months to see the tumor start to melt away, but in both ocular melanoma and retinoblastoma, the plaques usually deal the cancer a fatal blow.

"The radiation causes damage within the cancer cells that prevents them from proliferating and spreading," he says. "By the time we take off the plaque, the cancer cells are either dead or mortally wounded, even though we do not immediately see a difference in the appearance of the tumor. After the plaque therapy, as the cancer cells try to proliferate and divide, those cells die, which we then notice in follow-up exams as the tumor shrinks over time."

Harbour still begins treatment with , but when tumors are too big or unresponsive, the plaques provide a new option that has delivered positive results. Some children even can return to 20/20 vision depending on the size and location of the tumor, he says.

Related Stories

Recommended for you

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.